A pilot study investigating the efficacy of botanical anti‐inflammatory agents in an OTC eczema therapy

Zoe Diana Draelos

Eczema is a frequently encountered dermatologic condition characterized by inflammation resulting in erythema, scaling, induration, and lichenification. The objective of this research was to examine the roll of botanical anti-inflammatories in alleviating the signs and symptoms of mild-to-moderate eczema. A total of 25 subjects 18+ years of age with mild-to-moderate eczema were asked to leave all oral medications and cleansers unchanged substituting the botanical study moisturizer for all topical treatment three times daily for 2 weeks. Investigator, subject, and noninvasive assessments were obtained at baseline and week 2. There was a highly statistically significant (P < 0.001) improvement in investigator-assessed irritation, erythema, desquamation, roughness, dryness, lichenification, itching, and overall skin appearance after 2 weeks of botanical anti-inflammatory moisturizer use. Overall, a 79% reduction in itching was noted. Skin hydration as measured by corneometry increased 44% increase (P < 0.001). The study moisturizer containing the occlusive ingredients of dimethicone and shea butter oil; the humectant ingredients of glycerin, vitamin B, sodium PCA, and sodium hyaluronate; the barrier repair ingredients of ceramide 3, cholesterol, phytosphingosine, ceramide 6 II, and ceramide 1; and the botanical anti-inflammatories allantoin and bisabolol were helpful in reducing the signs and symptoms of mild-to-moderate eczema.